ALT

Altimmune, Inc.

9.21 USD
+0.01 (+0.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Altimmune, Inc. stock is down -0.75% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Feb 16:05 15 Mar, 2024 12.00 PUT 127 356
15 Feb 19:17 21 Jun, 2024 9.00 CALL 160 334
15 Feb 19:32 21 Jun, 2024 9.00 PUT 162 489
15 Feb 20:15 17 Jan, 2025 10.00 PUT 78 470
16 Feb 15:23 21 Jun, 2024 8.00 CALL 100 756
16 Feb 16:15 17 Jan, 2025 10.00 CALL 122 4598
16 Feb 20:58 17 Jan, 2025 5.00 CALL 50 1149
20 Feb 17:09 17 Jan, 2025 10.00 CALL 74 4472
23 Feb 16:05 21 Jun, 2024 14.00 CALL 200 2047
23 Feb 18:09 17 Jan, 2025 3.00 CALL 70 742

About Altimmune, Inc.

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.